Daily Stock Analysis, CNAT, Conatus Pharmaceuticals Inc, priceseries

Conatus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.10
Close
4.27
High
4.30
Low
4.05
Previous Close
4.09
Daily Price Gain
0.18
YTD High
9.40
YTD High Date
Apr 28, 2017
YTD Low
3.88
YTD Low Date
Dec 7, 2017
YTD Price Change
-1.12
YTD Gain
-20.78%
52 Week High
9.40
52 Week High Date
Apr 28, 2017
52 Week Low
1.88
52 Week Low Date
Dec 16, 2016
52 Week Price Change
2.36
52 Week Gain
123.56%
Company Information
Stock Symbol
CNAT
Exchange
NasdaqGM
Company URL
http://www.conatuspharma.com
Company Phone
(858) 376-2600
CEO
Steven J. Mento
Headquarters
California
Business Address
16745 WEST BERNARDO DRIVE, Suite 200, San Diego, CA 92127
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001383701
About

Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.